Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Roivant and Pulmovant said results from the Phase 2 PHocus study of mosliciguat in pulmonary hypertension associated with interstitial lung disease will be presented at ERS Congress 2026 on Tuesday, Sept. 8, 2026, plus an investor call.
ROIV ROIVW - Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call